Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658Phase 2Recruiting
- Sponsor
- MBrace Therapeutics
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MBRC-101 in solid tumor, non-small cell lung cancer (NSCLC), breast cancer, pancreatic adenocarcinoma (PDAC), gastric adenocarcinoma, sponsored by MBrace Therapeutics. Started Nov 2023; status: recruiting.
02
Drugs
MBRC-101
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancerpancreatic adenocarcinoma (PDAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT06014658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014658.